Cellectis SA (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CLLS Nasdaq 8731 http://www.cellectis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cellectis SA (ADR)

Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares - Feb 8th, 2023 12:01 am
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information - Feb 3rd, 2023 2:33 pm
Cellectis Announces Pricing of Follow-On Offering - Feb 3rd, 2023 5:48 am
Cellectis Announces Launch of Follow-On Offering - Feb 2nd, 2023 9:01 pm
7 CRISPR Stocks With the Best Long-Term Potential - Jan 31st, 2023 12:10 am
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics - Jan 20th, 2023 9:30 pm
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement - Jan 17th, 2023 12:10 pm
Monthly information on share capital and company voting rights - Jan 9th, 2023 9:30 pm
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq - Jan 4th, 2023 10:08 pm
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases - Dec 29th, 2022 9:30 pm
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities - Dec 28th, 2022 9:30 pm
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL - Dec 22nd, 2022 9:30 pm
Cellectis Touts Positive Preliminary Data From Two Leukemia Trials - Dec 13th, 2022 6:47 pm
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML - Dec 13th, 2022 12:30 pm
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022 - Dec 1st, 2022 9:40 pm
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022 - Nov 10th, 2022 2:05 pm
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE) - Nov 10th, 2022 7:48 am
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil - Nov 4th, 2022 4:31 pm
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022 - Nov 3rd, 2022 8:36 pm
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022 - Nov 3rd, 2022 8:05 pm